Replimune Group Future Growth

Future criteria checks 2/6

Replimune Group is forecast to grow earnings and revenue by 21% and 57.4% per annum respectively while EPS is expected to grow by 26.7% per annum.

Key information

21.0%

Earnings growth rate

26.7%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	57.4%
Future return on equity	n/a
Analyst coverage	Good
Last updated	22 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:7R8 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	101	-201	-235	N/A	3
3/31/2026	39	-227	-197	-147	5
3/31/2025	8	-221	-200	-156	7
9/30/2024	N/A	-213	-188	-181	N/A
6/30/2024	N/A	-220	-193	-186	N/A
3/31/2024	N/A	-216	-191	-185	N/A
12/31/2023	N/A	-210	-176	-172	N/A
9/30/2023	N/A	-199	-157	-154	N/A
6/30/2023	N/A	-182	-145	-143	N/A
3/31/2023	N/A	-174	-130	-128	N/A
12/31/2022	N/A	-157	-121	-118	N/A
9/30/2022	N/A	-147	-111	-108	N/A
6/30/2022	N/A	-133	-100	-97	N/A
3/31/2022	N/A	-118	-85	-82	N/A
12/31/2021	N/A	-108	-78	-76	N/A
9/30/2021	N/A	-100	-72	-70	N/A
6/30/2021	N/A	-91	-66	-65	N/A
3/31/2021	N/A	-81	-64	-61	N/A
12/31/2020	N/A	-75	-59	-57	N/A
9/30/2020	N/A	-70	-66	-59	N/A
6/30/2020	N/A	-61	-69	-62	N/A
3/31/2020	N/A	-53	-67	-61	N/A
12/31/2019	N/A	-43	-62	-55	N/A
9/30/2019	N/A	-35	-49	-46	N/A
6/30/2019	N/A	-30	-35	-32	N/A
3/31/2019	N/A	-31	-28	-25	N/A
12/31/2018	N/A	-31	-24	-24	N/A
9/30/2018	N/A	-28	-20	-20	N/A
6/30/2018	N/A	-26	N/A	-17	N/A
3/31/2018	N/A	-20	N/A	-16	N/A
12/31/2017	N/A	-17	N/A	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7R8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 7R8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 7R8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 7R8's revenue (57.4% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 7R8's revenue (57.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 7R8's Return on Equity is forecast to be high in 3 years time

Replimune Group Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies